St18 is a negative regulator of VEGF

St18 is a negative regulator of VEGF
St18 inhibits VEGF expression via Sp1 suppression. Credit: Kenta Maruyama

Pro-inflammatory cytokines and pathogen-associated molecular patterns such as lipopolysaccharide (LPS) are known to activate NF-kB. NF-kB is a master regulator of inflammation and induces pro-inflammatory cytokines. Although LPS-induced pro-inflammatory cytokiens are indispensable for host defense against pathogens, dysregulated production can lead to septic shock. Septic shock is the most common cause of death in intensive care unit.

Pro- in a systemic scale inflammatory response result in increased capillary permeability and low blood pressure. However, despite injection of anti-pro-inflammatory cytokine antibody into human , mortality rates remain high. Other than , macrophages can secrete (VEGF) in response to LPS. VEGF was initially described as a stimulator of endothelial permeability. VEGF was subsequently reported to promote proliferation and survival of endothelial cells, and is now thought to be the pivotal regulator of angiogenesis and vascular leakage. Notably, VEGF exaggerates septic inflammation, and human serum VEGF level can be used as a predictor of septic prognosis. Thus, not only pro-inflammatory cytokines but also VEGF play critical roles for septic pathophysiology.

Recently, Suppression of tumorigenicity 18 (St18) was discovered as a putative regulator of pro-inflammatory cytokine signaling. St18 is also reported as a candidate tumor suppressor in human breast tumors, because its expression is significantly down regulated in these cells compared to normal breast tissues. Conversely, St18 expression is up regulated in liver cancers, indicating an oncogenic function of this gene. Despite the pleiotropic functions of St18 in cancers, little is known about its functions in myeloid lineages. Maruyama and colleagues discovered that St18 is expressed in myeloid cells.

Unexpectedly, mice lacking St18 in myeloid lineages exhibit increased retinal vasculature with enhanced serum VEGF concentrations, and pharmacological inhibition of VEGF signaling rescued the high mortality rate of septic shock. Mechanistically, St18 bound to Sp1 and attenuated its activity, leading to the suppression of Sp1 target gene VEGF. Thus, myeloid St18-mediated may be a promising strategy for the development of therapeutics to control VEGF-associated disorders.


Explore further

The subcellular dynamics of RNA stabilizing molecule in response to inflammation

More information: Kenta Maruyama et al, Zinc Finger Protein St18 Protects against Septic Death by Inhibiting VEGF-A from Macrophages, Cell Reports (2020). DOI: 10.1016/j.celrep.2020.107906
Journal information: Cell Reports

Provided by National Institutes of Natural Sciences
Citation: St18 is a negative regulator of VEGF (2020, July 16) retrieved 30 October 2020 from https://medicalxpress.com/news/2020-07-st18-negative-vegf.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments